FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-analysis of 2618 cases and 2305 controls

Table 2 Stratified analyses of the FGFR4 Gly³⁸⁸Arg polymorphism on cancer risk

Variables	na	Cases/controls	Arg vs. Gly		Arg/Arg vs. Gly/Gly		Gly/Arg+Arg/Arg vs. Gly/Gly		Arg/Arg vs. Gly/Gly+ Gly/Arg
			OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb	OR (95% CI)	Pb
Total	5	2618/2305	1.17 (1.07-1.29)	0.37	1.39 (0.97-1.99)	0.08	1.21 (1.08-1.36)	0.79	1.32 (0.90-1.94)c	0.03
Caucasian	3	1935/1787	1.21 (1.00-1.47)	0.09	1.40 (0.80-2.45)c	0.04	1.23 (1.08-1.40)	0.39	1.26 (0.72-2.19)c	0.04
African	2	191/174	1.15 (0.73-1.82)	0.95	2.17 (0.20-23.14)	0.17	1.11 (0.66-1.86)	0.62	2.21 (0.18-26.83)	0.15
Asian	1	492/344	1.24 (1.02-1.51)	-	1.52 (1.05-2.22)	-	1.15 (0.86-1.54)	-	1.53 (1.10-2.14)	-
Tumor stage
Localized			1.00 (reference)		1.00 (reference)		1.00 (reference)		1.00 (reference)
Advanced			1.18 (0.96-1.44)	0.75	1.33 (0.91-1.96)	0.89	1.01 (0.93-1.10)	0.44	1.34 (1.03-1.74)	0.61

^aNumber of comparisons; ^b P value of Q-test for heterogeneity test; ^cRandom-effects model was used when P value for heterogeneity test < 0.05; otherwise, fixed-effects model was used;

ISSN: 1471-2407